Puma Biotechnology Holds Annual Stockholders Meeting 2025

Puma Biotechnology ( (PBYI) ) has shared an update.

On June 11, 2025, Puma Biotechnology held its 2025 Annual Meeting of Stockholders at its executive offices in Los Angeles, California. During the meeting, stockholders elected eight directors for a one-year term, ratified KPMG LLP as the independent accounting firm for the fiscal year ending December 31, 2025, and approved the compensation of the company’s named executive officers.

The most recent analyst rating on (PBYI) stock is a Sell with a $2.00 price target. To see the full list of analyst forecasts on Puma Biotechnology stock, see the PBYI Stock Forecast page.

Spark’s Take on PBYI Stock

According to Spark, TipRanks’ AI Analyst, PBYI is a Neutral.

Puma Biotechnology’s overall stock score reflects its financial improvements, technical momentum, and attractive valuation. However, the company’s challenges with revenue consistency and leverage, combined with mixed earnings call insights, temper the outlook. Long-term prospects may depend on successful execution of strategic initiatives and stabilization of revenue.

To see Spark’s full report on PBYI stock, click here.

More about Puma Biotechnology

Puma Biotechnology, Inc. is a company operating in the biotechnology industry, focusing on the development and commercialization of innovative products for the treatment of cancer.

Average Trading Volume: 359,045

Technical Sentiment Signal: Hold

Current Market Cap: $175.7M

For an in-depth examination of PBYI stock, go to TipRanks’ Overview page.